Theravance Biopharma Inc (TBPH)
Theravance Biopharma Inc. (NASDAQ: TBPH) is a healthcare company focused on developing and commercializing medicines in the United States. Its marketed product portfolio includes YUPELRI, a once-daily nebulized long-acting muscarinic antagonist used in the treatment of chronic obstructive pulmonary disease (COPD). The company is also advancing Ampreloxetine, an investigational once-daily norepinephrine reuptake inhibitor being studied in Phase 3 trials for symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy. Theravance Biopharma has a strategic collaboration with Viatris Inc. related to the development and commercialization of revefenacin, including YUPELRI inhalation solution. Incorporated in 2013, the company is based in South San Francisco, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TBPH
|
$14.85
|
-12.0% Downside
|
Fair
|
$17.67
|
4.7% Upside
|
Fair
|
Great
|
—
|
—
|
—
|
0.0%
|
August 5, 2026
|
7.6x
|
3.0x
|
8.0x
|
871.2 M
|
521.2 M
|
4.4%
|
46.8%
|
1.6
|
—
|
234.6%
|
